| Emerging role of ctDNA in solid tumors How the latest data may impact your practice to better stratify colorectal cancer patients |
|
|
| Join John Marshall, MD and Alexey Aleshin, MD in an engaging discussion as they review exciting new data and its real-world application: Learn how the latest data can be applied to better stratify high risk patients
Review real-world evidence and the emerging role of ctDNA to monitor GI cancers
How to use ctDNA in your practice for early recurrence detection
|
|
|
John L. Marshall, MD
Medical Oncologist,
Washington, DC
|
Alexey Aleshin, MD
Sr. Medical Director,
Oncology - Natera
| | |
| If you are attending ASCO GI, check out the new data we are presenting:
Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.
Oral Abstract Session: Anal and Colorectal Cancer
January 16, 2021 9:00 AM-10:15 AM ET
Abstract # 11 |
|
|
| |
Tenna V Henriksen, MSc Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark
|
|
Minimal Residual Disease detection with Circulating Tumor DNA from personalized assays in stage II-III Colorectal Cancer patients in a UK multicentre prospective study (TRACC)
Available for view on January 15, 2021 8:00 AM ET
Abstract # 102 |
|
|
| |
Professor David Cunningham, MD FRCP FMedSci
The Royal Marsden NHS Foundation
|
|
| The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. |
|
|
|
|
